Medicare Benefits Schedule - Item 73332

Search Results for Item 73332

Category 6 - PATHOLOGY SERVICES

73332

73332 - Additional Information

Item Start Date:
01-May-2012
Description Updated:
01-Dec-2012
Schedule Fee Updated:
01-Jan-2013

Group
P7 - Genetics

An in situ hybridization (ISH) test of tumour tissue from a patient with breast cancer requested by, or on the advice of, a specialist or consultant physician who manages the treatment of the patient to determine if the requirements relating to human epidermal growth factor receptor 2 (HER2) gene amplification for access to trastuzumab under the Pharmaceutical Benefits Scheme (PBS) or the Herceptin Program are fulfilled.

Fee: $315.40 Benefit: 75% = $236.55 85% = $268.10


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change